32 related articles for article (PubMed ID: 37815490)
21. The role of the JAK/STAT3 signaling pathway in acquired corneal diseases.
Song D; Yang Q; Li X; Chen K; Tong J; Shen Y
Exp Eye Res; 2024 Jan; 238():109748. PubMed ID: 38081573
[TBL] [Abstract][Full Text] [Related]
22. Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
Su Q; Huang P; Luo X; Zhang P; Li H; Chen Y
Hematology; 2023 Dec; 28(1):2255802. PubMed ID: 37815490
[TBL] [Abstract][Full Text] [Related]
23. High-dose cytarabine (HD araC) in the treatment of leukemias: a review.
Reese ND; Schiller GJ
Curr Hematol Malig Rep; 2013 Jun; 8(2):141-8. PubMed ID: 23666364
[TBL] [Abstract][Full Text] [Related]
24. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).
Fernandez-Calotti P; Jordheim LP; Giordano M; Dumontet C; Galmarini CM
Leuk Lymphoma; 2005 Mar; 46(3):335-46. PubMed ID: 15621823
[TBL] [Abstract][Full Text] [Related]
25. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
26. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
Venugopal S; Bar-Natan M; Mascarenhas JO
Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
[TBL] [Abstract][Full Text] [Related]
27. The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia.
Moser B; Edtmayer S; Witalisz-Siepracka A; Stoiber D
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440253
[TBL] [Abstract][Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
